Abstract
Mistletoe lectin I (ML-I) is a heterodimeric ribosome-inactivating protein composed of a sialic acid-specific Bchain that binds to cell surfaces, and an A-chain with the capacity to depurinate a critical adenosine in the 28S ribosomal RNA. ML-1, in purified or recombinant form, exerts an immunomodulatory effect on neutrophils and macrophages/ monocytes in the low-dose range, while at high doses, it induces apoptosis in both normal and tumoral cells. While mistletoe extracts are widely used as cancer adjuvant therapy, recombinant ML-I (rAviscumin) is a candidate antineoplastic agent that has successfully passed Phase I clinical trials. In immunodeficient mouse models, the efficacy of recombinant ML-I was demonstrated for ovarian carcinoma, melanoma and various hematological malignant cell lines. The clinical potential of recombinant ML-I as a non-mutagenic and non-genotoxic molecule is high and could be used to potentiate classical anti-neoplastic drugs. Its capacity to induce apoptosis in cancer cell lines lacking p53 allows considering its use against genetically unstable and highly metastatic cancers. The mechanisms of apoptosis induced by ML-I probably involves intracellular pathways akin to those described as the “ribotoxic stress response” that directly target the mitochondrion.
Current Organic Chemistry
Title: Mistletoe Lectins: Carbohydrate-Specific Apoptosis Inducers and Immunomodulators
Volume: 12 Issue: 11
Author(s): Daniel C. Hoessli and Ishtiaq Ahmad
Affiliation:
Abstract: Mistletoe lectin I (ML-I) is a heterodimeric ribosome-inactivating protein composed of a sialic acid-specific Bchain that binds to cell surfaces, and an A-chain with the capacity to depurinate a critical adenosine in the 28S ribosomal RNA. ML-1, in purified or recombinant form, exerts an immunomodulatory effect on neutrophils and macrophages/ monocytes in the low-dose range, while at high doses, it induces apoptosis in both normal and tumoral cells. While mistletoe extracts are widely used as cancer adjuvant therapy, recombinant ML-I (rAviscumin) is a candidate antineoplastic agent that has successfully passed Phase I clinical trials. In immunodeficient mouse models, the efficacy of recombinant ML-I was demonstrated for ovarian carcinoma, melanoma and various hematological malignant cell lines. The clinical potential of recombinant ML-I as a non-mutagenic and non-genotoxic molecule is high and could be used to potentiate classical anti-neoplastic drugs. Its capacity to induce apoptosis in cancer cell lines lacking p53 allows considering its use against genetically unstable and highly metastatic cancers. The mechanisms of apoptosis induced by ML-I probably involves intracellular pathways akin to those described as the “ribotoxic stress response” that directly target the mitochondrion.
Export Options
About this article
Cite this article as:
Hoessli C. Daniel and Ahmad Ishtiaq, Mistletoe Lectins: Carbohydrate-Specific Apoptosis Inducers and Immunomodulators, Current Organic Chemistry 2008; 12 (11) . https://dx.doi.org/10.2174/138527208784892196
DOI https://dx.doi.org/10.2174/138527208784892196 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
Call for Papers in Thematic Issues
Advances of Heterocyclic Chemistry with Pesticide Activity
Global food safety and security will continue to be a global concern for the next 50 years and beyond. Plant diseases have had a significant impact on food safety and security throughout the entire food chain, from primary production to consumption. While conventional chemical pesticides have been traditionally used for ...read more
Calculation design of covalent/metal organic framework based catalysts
This research area combines theoretical computation and screening with machine learning for the design of covalent/metal organic framework-based catalysts, bridging the disciplines of organic chemistry, physical chemistry, computational chemistry, materials science, and machine learning. It covers several critical aspects: designing and synthesizing organic catalysts for improved performance, applying computational methods ...read more
Carbohydrates conversion in biofuels and bioproducts
Biomass pretreatment, hydrolysis, and saccharification of carbohydrates, and sugars bioconversion in biofuels and bioproducts within a biorefinery framework. Carbohydrates derived from woody biomass, agricultural wastes, algae, sewage sludge, or any other lignocellulosic feedstock are included in this issue. Simulation, techno-economic analysis, and life cycle analysis of a biorefinery process are ...read more
Catalytic C-H bond activation as a tool for functionalization of heterocycles
The major topic is the functionalization of heterocycles through catalyzed C-H bond activation. The strategies based on C-H activation not only provide straightforward formation of C-C or C-X bonds but, more importantly, allow for the avoidance of pre-functionalization of one or two of the cross-coupling partners. The beneficial impact of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Proteasome as an Emerging Therapeutic Target in Cancer
Current Pharmaceutical Design Toll-Like Receptors and their Role in Hematologic Malignancies
Current Molecular Medicine JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry Resveratrol as an Enhancer of Apoptosis in Cancer: A Mechanistic Review
Anti-Cancer Agents in Medicinal Chemistry The Role of CXC-Chemokine IL-8, IL-6 and CXCR2 Receptor in Lymphoplasmacytic Lymphoma: Correlations with Microvascular Characteristics and Clinical Features
Current Angiogenesis (Discontinued) Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Proteomics to Study Candida albicans Biology and Pathogenicity
Infectious Disorders - Drug Targets Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia
Current Drug Targets A Possible Approach for Stem Cell Gene Therapy of Fanconi Anemia
Current Gene Therapy Role of Genetic and Epigenetic Factors in Oral Squamous Cell Carcinoma - A Structured Review
Recent Patents on Biomarkers The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells
Current Drug Metabolism Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry DNA Demethylation by TET Proteins: A Potential Therapeutic Target in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets SHP2 Inhibition Benefits Epidermal Growth Factor Receptor-mutated Non-Small Cell Lung Cancer Therapy
Mini-Reviews in Medicinal Chemistry Current Treatment Concepts of CML
Current Cancer Drug Targets